GlassScriptPhysician profile
Thomas Allen Moore
NPI 1407851181
$37,198.16
in general payments reported to CMS, 2019-2025
26 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $13.48 · 2021: $103 · 2022: $93.60 · 2023: $243 · 2024: $34K · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $3,515 · Food and Beverage: $1,090 · Consulting Fee: $40.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,100.00 |
| Travel and Lodging | $3,514.73 |
| Food and Beverage | $1,090.15 |
| Consulting Fee | $40.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $35,984.18 | 2024-2025 | Zenpep |
| Abbvie INC. | $203.00 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.11 | 2022-2024 | Hyqvia |
| Melinta Therapeutics, LLC | $96.15 | 2019-2025 | Vabomere, Kimyrsa, Rezzayo |
| Pfizer INC. | $66.04 | 2023-2025 | |
| Octapharma USA, INC. | $62.41 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Adma Biomanufacturing LLC | $60.05 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.05 | 2019 | |
| Insmed, INC. | $54.90 | 2021-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $51.35 | 2019-2024 | Dificid, Zerbaxa, Zinplava |
| Paratek Pharmaceuticals, INC. | $50.69 | 2024-2025 | Nuzyra |
| Allergan, INC. | $44.01 | 2019 | |
| Gilead Sciences, INC. | $42.08 | 2024 | |
| Hospira, INC. | $34.92 | 2024 | |
| Grifols USA, LLC | $34.00 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $33.13 | 2019 | |
| Viiv Healthcare Company | $32.66 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $27.62 | 2023 | Rebyota |
| Davol INC. | $25.90 | 2023 | Arista Ah Flexitip |
| Nestle Healthcare Nutrition INC. | $22.04 | 2023 | |
| Shionogi INC | $19.48 | 2023 | Fetroja |
| Amgen INC. | $17.41 | 2024 | Actimmune |
| Csl Behring | $17.32 | 2025 | Hizentra |
| Convatec INC. | $15.87 | 2023 | |
| Cormedix INC. | $15.54 | 2024 | Defencath |
| Astellas Pharma US INC | $14.25 | 2023 | Cresemba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.